[Palliation of urothelial carcinoma of the bladder].
Bladder cancer is a disease that occurs late in life (> 50% of the patients in Germany are 70 years or older). The general condition of the patients is frequently reduced, aggressive therapy of advanced tumours stages is therefore often contra-indicated. In this situation, palliative treatment is of extraordinary importance. Strangely enough, controlled prospective trials are lacking. They are, however, necessary in order to establish, or improve, standards of palliative treatment. Several smaller studies proved the potential of bladder irrigation and the embolisation of A. iliaca to stop bleeding from the tumourous bladder. If the tumour causes urinary retention, a permanent ureteral stent may in certain cases help to guarantee adequate flow. The assessment of palliative radiotherapy is not possible due to small numbers of (and highly selected) patients. It may have a potential in cases of hematuria, pain, and incontinence. New anti-tumour agents (e.g. Gemcitabine) may turn out to be a tolerable and effective palliative.
Weissbach
L
L
Urologische Abteilung, Krankenhaus Am Urban, Dieffenbachstrasse 1, 10967 Berlin. lothar.weissbach@kau-berlin.de
D000368:Aged; D000534:Alum Compounds / Q000008:administration & dosage; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D004621:Embolization, Therapeutic; D005260:Female; D006417:Hematuria / Q000628:therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010166:Palliative Care; D015607:Stents; D015996:Survival Rate; D007507:Therapeutic Irrigation; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D000534:Alum Compounds; C041524:aluminum sulfate
Zur Palliation des Urothelkarzinoms der Harnblase.